Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy-Reference-Cited by-同舟云学术

Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy

Published:2019-11 Issue:45 Volume:98 Page:e17931
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Park Jee Soo,Koo Kyo Chul,Choi In Young,Lee Ji Youl,Hong Jun Hyuk,Kim Choung-Soo,Lee Hyun Moo,Hong Sung Kyu,Byun Seok-Soo,Rha Koon Ho,Chung Byung Ha,Lee Kwang Suk

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference25 articles.

1. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC;Wolters;Int J Cancer,2010

2. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up;Andriole;J Natl Cancer Inst,2012

3. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial;Thompson;J Urol,2009

4. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95;Wiegel;J Clin Oncol,2009

5. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911);Bolla;Lancet,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Multiparametric Magnetic Resonance Imaging-Based Deep Learning and Clinical Parameter Integration for the Prediction of Long-Term Biochemical Recurrence-Free Survival in Prostate Cancer after Radical Prostatectomy;Cancers;2023-06-29

2. Prostate-specific antigen density as a predictor of recurrence-free survival following combined hormonal-radiation therapy of localized prostate cancer;Cancer Urology;2022-12-09